{"id":25392,"date":"2024-04-03T14:51:12","date_gmt":"2024-04-03T14:51:12","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=25392"},"modified":"2025-12-01T14:57:10","modified_gmt":"2025-12-01T13:57:10","slug":"crispr-cas13-2","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/pl\/crispr-cas13-2\/","title":{"rendered":"CRISPR-Cas13"},"content":{"rendered":"<p><strong>Rewolucyjna technologia o wysokim potencjale dla zespo\u0142u duplikacji genu MECP2 <\/strong><\/p>\n\n<p>\u015awiat in\u017cynierii genetycznej zosta\u0142 zrewolucjonizowany przez pojawienie si\u0119 technologii CRISPR. W\u015br\u00f3d r\u00f3\u017cnych typ\u00f3w system\u00f3w CRISPR, CRISPR-Cas13 wyr\u00f3\u017cnia si\u0119 unikaln\u0105 zdolno\u015bci\u0105 do celowania w informacyjny RNA, w przeciwie\u0144stwie do innych system\u00f3w, kt\u00f3re celuj\u0105 w DNA. W niniejszym artykule om\u00f3wiono technologi\u0119 CRISPR-Cas13 i jej potencjalne zastosowanie w leczeniu zespo\u0142u duplikacji genu MECP2.<\/p>\n\n<p><strong>CRISPR-Cas13: kr\u00f3tki przegl\u0105d<\/strong><\/p>\n\n<p>CRISPR-Cas13 jest cz\u0119\u015bci\u0105 systemu CRISPR, rewolucyjnego narz\u0119dzia, kt\u00f3re zmieni\u0142o dziedzin\u0119 in\u017cynierii genetycznej. CRISPR-Cas13 jest wyj\u0105tkowy, poniewa\u017c jego celem s\u0105 cz\u0105steczki informacyjnego RNA, po\u015brednie mi\u0119dzy DNA a bia\u0142kami. Umo\u017cliwia to bardziej dynamiczne i odwracalne podej\u015bcie do modyfikacji genetycznej, poniewa\u017c modyfikacje RNA nie zmieniaj\u0105 trwale genomu.<\/p>\n\n<p>Bia\u0142ko Cas13 jest kierowan\u0105 przez RNA endonukleaz\u0105, kt\u00f3ra niszczy cz\u0105steczki RNA. Mo\u017cna j\u0105 zaprogramowa\u0107 za pomoc\u0105 prowadz\u0105cego RNA, aby celowa\u0142a i ci\u0119\u0142a dowoln\u0105 sekwencj\u0119 RNA, co czyni j\u0105 wszechstronnym narz\u0119dziem do bada\u0144 genetycznych i potencjalnych zastosowa\u0144 terapeutycznych.<\/p>\n\n<p><strong>Rola AAV w podawaniu CRISPR-Cas13<\/strong><\/p>\n\n<p>W kontek\u015bcie zespo\u0142u duplikacji MECP2 istotnym sk\u0142adnikiem systemu CRISPR-Cas13 jest wektor wykorzystywany do jego dostarczania - wirus adenowirusowy (AAV). AAV s\u0105 popularnymi wektorami w terapii genowej ze wzgl\u0119du na ich zdolno\u015b\u0107 do dostarczania gen\u00f3w do kom\u00f3rek przy minimalnej odpowiedzi immunologicznej. W przypadku CRISPR-Cas13, wektor AAV jest wykorzystywany do dostarczania bia\u0142ka Cas13 i jego RNA do kom\u00f3rek. Umo\u017cliwia to systemowi dotarcie do docelowych cz\u0105steczek RNA i wykonanie funkcji rozszczepiania.<\/p>\n\n<p><strong>Podawanie lek\u00f3w<\/strong><\/p>\n\n<p>W celu zwi\u0119kszenia biodost\u0119pno\u015bci lek jest podawany bezpo\u015brednio do m\u00f3zgu. Metoda ta zapewnia, \u017ce wy\u017csze st\u0119\u017cenie leku dociera do miejsca docelowego, zwi\u0119kszaj\u0105c jego skuteczno\u015b\u0107.<\/p>\n\n<p><strong>CRISPR-Cas13 w zespole duplikacji genu MECP2<\/strong><\/p>\n\n<p>Potencja\u0142 CRISPR-Cas13 w leczeniu zespo\u0142u duplikacji genu MECP2 polega na jego zdolno\u015bci do celowania i degradacji dodatkowego mRNA MECP2 wytwarzanego w wyniku duplikacji genu. Zmniejszaj\u0105c poziom bia\u0142ka MeCP2, mo\u017ce potencjalnie z\u0142agodzi\u0107 objawy zespo\u0142u.<\/p>\n\n<p><strong>Wnioski<\/strong><\/p>\n\n<p>CRISPR-Cas13 stanowi obiecuj\u0105ce narz\u0119dzie do leczenia zaburze\u0144 genetycznych, takich jak zesp\u00f3\u0142 duplikacji.<em> <\/em>genu MECP2. Celuj\u0105c w pierwotn\u0105 przyczyn\u0119 zaburzenia na poziomie RNA, oferuje potencjaln\u0105 strategi\u0119 terapeutyczn\u0105, kt\u00f3ra mo\u017ce poprawi\u0107 jako\u015b\u0107 \u017cycia pacjent\u00f3w. Opr\u00f3cz zespo\u0142u duplikacji MECP2, potencjalne zastosowania CRISPR-Cas13 s\u0105 ogromne, w tym w leczeniu innych zaburze\u0144 neurologicznych, takich jak choroba Alzheimera, zesp\u00f3\u0142 Angelmana* itp. <\/p>\n\n<p><em>*Jinhui Li, Hui Yang. Cas13 o wysokiej wierno\u015bci ukierunkowany na RNA przywraca ekspresj\u0119 ojcowskiego Ube3a i poprawia funkcje motoryczne u myszy z zespo\u0142em Angelmana. Molecular Therapy. 2023 Jul 5; 31 (7): 2286-2295.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Une technologie r\u00e9volutionnaire \u00e0 haut potentiel dans le syndrome de duplication du g\u00e8ne MECP2 Le monde du g\u00e9nie g\u00e9n\u00e9tique a \u00e9t\u00e9 r\u00e9volutionn\u00e9 par l&rsquo;av\u00e8nement de la technologie CRISPR. Parmi les [&hellip;]<\/p>","protected":false},"author":1,"featured_media":4720,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-25392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CRISPR-Cas13 - DupMECP2<\/title>\n<meta name=\"description\" content=\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l&#039;ARN messager, contrairement \u00e0 d&#039;autres syst\u00e8mes qui ciblent l&#039;ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/pl\/crispr-cas13-2\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR-Cas13 - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l&#039;ARN messager, contrairement \u00e0 d&#039;autres syst\u00e8mes qui ciblent l&#039;ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/pl\/crispr-cas13-2\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T14:51:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T13:57:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1637\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"CRISPR-Cas13\",\"datePublished\":\"2024-04-03T14:51:12+00:00\",\"dateModified\":\"2025-12-01T13:57:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"},\"wordCount\":531,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"pl-PL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\",\"url\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\",\"name\":\"CRISPR-Cas13 - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"datePublished\":\"2024-04-03T14:51:12+00:00\",\"dateModified\":\"2025-12-01T13:57:10+00:00\",\"description\":\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"width\":2560,\"height\":1637},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CRISPR-Cas13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/pl\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR-Cas13 - DupMECP2","description":"W\u015br\u00f3d r\u00f3\u017cnych typ\u00f3w system\u00f3w CRISPR, CRISPR-Cas13 wyr\u00f3\u017cnia si\u0119 unikaln\u0105 zdolno\u015bci\u0105 do celowania w informacyjny RNA, w przeciwie\u0144stwie do innych system\u00f3w, kt\u00f3re celuj\u0105 w DNA. W niniejszym artykule om\u00f3wiono technologi\u0119 CRISPR-Cas13 i jej potencjalne zastosowanie w leczeniu zespo\u0142u duplikacji genu MECP2.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/pl\/crispr-cas13-2\/","og_locale":"pl_PL","og_type":"article","og_title":"CRISPR-Cas13 - DupMECP2","og_description":"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.","og_url":"https:\/\/dupmecp2.eu\/pl\/crispr-cas13-2\/","og_site_name":"DupMECP2","article_published_time":"2024-04-03T14:51:12+00:00","article_modified_time":"2025-12-01T13:57:10+00:00","og_image":[{"width":2560,"height":1637,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"Caroline","Szacowany czas czytania":"3 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"CRISPR-Cas13","datePublished":"2024-04-03T14:51:12+00:00","dateModified":"2025-12-01T13:57:10+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/"},"wordCount":531,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"pl-PL"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/","url":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/","name":"CRISPR-Cas13 - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","datePublished":"2024-04-03T14:51:12+00:00","dateModified":"2025-12-01T13:57:10+00:00","description":"W\u015br\u00f3d r\u00f3\u017cnych typ\u00f3w system\u00f3w CRISPR, CRISPR-Cas13 wyr\u00f3\u017cnia si\u0119 unikaln\u0105 zdolno\u015bci\u0105 do celowania w informacyjny RNA, w przeciwie\u0144stwie do innych system\u00f3w, kt\u00f3re celuj\u0105 w DNA. W niniejszym artykule om\u00f3wiono technologi\u0119 CRISPR-Cas13 i jej potencjalne zastosowanie w leczeniu zespo\u0142u duplikacji genu MECP2.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/crispr-cas13-2\/"]}]},{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","width":2560,"height":1637},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"CRISPR-Cas13"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/pl\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/25392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/comments?post=25392"}],"version-history":[{"count":1,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/25392\/revisions"}],"predecessor-version":[{"id":33396,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/25392\/revisions\/33396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/media\/4720"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/media?parent=25392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/categories?post=25392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/tags?post=25392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}